全文获取类型
收费全文 | 2369967篇 |
免费 | 182971篇 |
国内免费 | 7766篇 |
专业分类
耳鼻咽喉 | 32179篇 |
儿科学 | 78104篇 |
妇产科学 | 66939篇 |
基础医学 | 334635篇 |
口腔科学 | 66397篇 |
临床医学 | 209462篇 |
内科学 | 472640篇 |
皮肤病学 | 53773篇 |
神经病学 | 190702篇 |
特种医学 | 94974篇 |
外国民族医学 | 626篇 |
外科学 | 367427篇 |
综合类 | 52947篇 |
现状与发展 | 3篇 |
一般理论 | 708篇 |
预防医学 | 185486篇 |
眼科学 | 52896篇 |
药学 | 172973篇 |
6篇 | |
中国医学 | 4279篇 |
肿瘤学 | 123548篇 |
出版年
2018年 | 23179篇 |
2016年 | 21021篇 |
2015年 | 23742篇 |
2014年 | 33142篇 |
2013年 | 50163篇 |
2012年 | 64448篇 |
2011年 | 69036篇 |
2010年 | 42227篇 |
2009年 | 40594篇 |
2008年 | 65486篇 |
2007年 | 70558篇 |
2006年 | 71951篇 |
2005年 | 70050篇 |
2004年 | 67159篇 |
2003年 | 65330篇 |
2002年 | 63181篇 |
2001年 | 108585篇 |
2000年 | 111800篇 |
1999年 | 94216篇 |
1998年 | 28075篇 |
1997年 | 25189篇 |
1996年 | 26056篇 |
1995年 | 25509篇 |
1994年 | 24076篇 |
1993年 | 22428篇 |
1992年 | 77798篇 |
1991年 | 76277篇 |
1990年 | 74215篇 |
1989年 | 71155篇 |
1988年 | 66345篇 |
1987年 | 65060篇 |
1986年 | 61921篇 |
1985年 | 59417篇 |
1984年 | 45012篇 |
1983年 | 38463篇 |
1982年 | 23771篇 |
1981年 | 21216篇 |
1980年 | 19912篇 |
1979年 | 41740篇 |
1978年 | 29855篇 |
1977年 | 25432篇 |
1976年 | 23716篇 |
1975年 | 25501篇 |
1974年 | 30025篇 |
1973年 | 28761篇 |
1972年 | 26959篇 |
1971年 | 24977篇 |
1970年 | 23012篇 |
1969年 | 21968篇 |
1968年 | 20661篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
Xenotransplantation is being developed in the hope of resolvingthe critical shortage of donor organs for transplantation. TheEurotransplant waiting lists [1] for donor organs of variouskinds number almost 16 000 patients and the US lists [2] morethan 90 000 patients. Renal transplantation, for instance, cost-effectivelyconfers a significant survival advantage [3] and improvementof quality of life [4]. But whereas currently, in Europe, nearly12 000 end-stage renal disease patients await a suitable donor,only 3383 kidney transplants were performed in 2005, with anaverage waiting time of 1174 days [1]. Substantial researchefforts are being made in the field of xenotransplantation,and the immunological barriers are gradually being elucidated.Pig-to-human xenogeneic 相似文献
992.
Yubin Miao Said D Figueroa Darrell R Fisher Herbert A Moore Richard F Testa Timothy J Hoffman Thomas P Quinn 《Journal of nuclear medicine》2008,49(5):823-829
Peptide-targeted alpha-therapy with 7.4 MBq of (212)Pb-[1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-ReO-[Cys(3,4,10),d-Phe(7),Arg(11)]alpha-MSH(3-13) ((212)Pb-DOTA-Re(Arg(11))CCMSH) cured 45% of B16/F1 murine melanoma-bearing C57 mice in a 120-d study, highlighting its melanoma treatment potential. However, there is a need to develop an imaging surrogate for patient-specific dosimetry and to monitor the tumor response to (212)Pb-DOTA-Re(Arg(11))CCMSH therapy. The purpose of this study was to evaluate the potential of (203)Pb-DOTA-Re(Arg(11))CCMSH as a matched-pair SPECT agent for (212)Pb-DOTA-Re(Arg(11))CCMSH. METHODS: DOTA-Re(Arg(11))CCMSH was labeled with (203)Pb in 0.5 M NH(4)OAc buffer at pH 5.4. The internalization and efflux of (203)Pb-DOTA-Re(Arg(11))CCMSH were determined in B16/F1 melanoma cells. The pharmacokinetics of (203)Pb-DOTA-Re(Arg(11))CCMSH was examined in B16/F1 melanoma-bearing C57 mice. A micro-SPECT/CT study was performed with (203)Pb-DOTA-Re(Arg(11))CCMSH in a B16/F1 melanoma-bearing C57 mouse at 2 h after injection. RESULTS: (203)Pb-DOTA-Re(Arg(11))CCMSH was easily prepared in NH(4)OAc buffer and completely separated from the excess nonradiolabeled peptide by reversed-phase high-performance liquid chromatography (RP-HPLC). (203)Pb-DOTA-Re(Arg(11))CCMSH displayed fast internalization and extended retention in B16/F1 cells. Approximately 73% of (203)Pb-DOTA-Re(Arg(11))CCMSH activity internalized after a 20-min incubation at 25 degrees C. After incubation of the cells in culture medium for 20 min, 78% of internalized activity remained in the cells. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a biodistribution pattern similar to that of (212)Pb-DOTA-Re(Arg(11))CCMSH in B16/F1 melanoma-bearing mice. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a peak tumor uptake of 12.00+/-3.20 percentage injected dose per gram (%ID/g) at 1 h after injection. The tumor uptake gradually decreased to 3.43+/-1.12 %ID/g at 48 h after injection. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a peak tumor-to-kidney uptake ratio of 1.53 at 2 h after injection. The absorbed doses to the tumor and kidneys were 4.32 and 4.35 Gy, respectively, per 37 MBq. Whole-body clearance of (203)Pb-DOTA-Re(Arg(11))CCMSH was fast, with approximately 89% of the injected activity cleared through the urinary system by 2 h after injection. (203)Pb showed 1.6-mm SPECT resolution, which was comparable to (99m)Tc. Melanoma lesions were visualized through SPECT/CT images of (203)Pb-DOTA-Re(Arg(11))CCMSH at 2 h after injection. CONCLUSION: (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited favorable pharmacokinetic and tumor imaging properties, highlighting its potential as a matched-pair SPECT agent for (212)Pb-DOTA-Re(Arg(11))CCMSH melanoma treatment. 相似文献
993.
994.
995.
996.
997.
998.
999.
1000.